The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.
Sustaining progress in the development of lifesaving cancer therapies will require aligning policy with science, advancing value-based care, and strengthening collaboration to ensure technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback